复星医药二零二三年中期报告

我們的願景 我們的使命 目錄 02040558676869717375111 戰略委員會 董事 審計委員會 提名委員會 薪酬與考核委員會 監事 12 聯席公司秘書 環境、社會及管治委員會 授權代表 註冊地點 5109200063 1202362822023628 中國主要營業地點 公司名稱 1289A200233 股票簡稱 香港主要營業地點 3485 股票上市地點 A600196H02196 香港法律顧問 中國A股過戶登記處 中國法律顧問 188 核數師 97927 香港H股過戶登記處 1617 本公司網站http://www.fosunpharma.com 主要往來銀行 財務回顧 21,3160.16%(1)2022355657.1%32.7%(2)mRNA15% 1,78415.69%1,37326.28%(1)(2)Gland Pharma(3)(4)381(5)307411731BNTX–3201,8100.63% 2,88419.77%2,13430716.80% 收入 21,3160.16%16,5304,78622.45% 15,92111.56%1,66012.17%1,4289.56% 銷售成本 10,699202211,5787.59%2022 毛利 10,61720229,7049.41%49.81%4.210.04 銷售及分銷開支 5,0714,17589621.46%23.79%4.170.04(1)(2)PD-1(Sisram Medical)(3) 行政開支 2,10322.13% 研發費用與研發投入 2,88419.77%2,13430716.80%2,51945722.16 %15.82%1,79230120.19%11.26% 其他收益及其他開支 85731.64%25671.93% 應佔聯營公司溢利 1,118202289924.36% 本期溢利 2,05120221,84910.92%20229.62%8.69% 歸屬母公司股東的本期溢利 1,309670Gland Pharma1,78415.69% 債務結構、流動性與資金來源 總債務 202363032,5662022123129,116202363035.86%2022123141.56%5.70降202363014,8852022123116,2418.35% 20236308,239202212317,875 20236303,903202212315,858 總債務佔總資產比率 202363029.05%2022123127.18% 利率 202363015,4922022123116,899 借用融資來源 202363014,88524,111202363055,43231,321 20227202286,0004,0002 抵押及質押資產 20236301,656202212311,28059620221231506509,00020221231 202363058.67%2022123158.67% 16 現金流量 2022 資本承諾及資本開支 2,7234 20236301,3142,02318 或有負債 2023630 利息倍數 EBITDA7.6620228.26 風險管理 匯率風險 利率風險 業務回顧 董事會關於本集團報告期內經營情況的討論與分析 21,3160.16%(1)2022355657.1%32.7%(2)mRNA15% 1,78415.69%1,37326.28%(1)(2)Gland Pharma(3)(4)381(5)307411731BNTX–3201,8100.63% 2,88419.77%2,13430716.80% 一、報告期內本集團主要經營進展 1. 5104134(NDA)7(IND)1 (ES-SCLC)(ES-SCLC)PD-112B(r/r LBCL) (P-CAB)202382023120233 2 PD-1(MAA)(BLA)FDADaxibotulinumtoxinART002202347Tenapanor(CKD)20237 2. 516PD-1Syneos Health(BLA)FDA22020ZercepacPD-1ES-SCLCAKYNZEOALOXI 40Gland PharmaCDMOBoston OncologyBoston Oncology1620238PD-1KGbio1012 (Sisram Medical)2023(Sisram Medical)72%(Sisram Medical)(Breas)(Breas)Vivo 123 3. 6,0002,00010,00020DTP 1,000PD-15B2B2C (ASCO)(CSCO)(EHA) 20231 ESG 4. AISRM(SupplierRelationship Management)SRMSRMSRMS2P(Source to Pay) eHRSAPGland PharmaTridem Pharma EHS 12023612B(r/r LBCL) 2 320231 420233PD-1(ES-SCLC)EMA 520233(Tenapanor) Accord BioPharma Inc.(BLA)FDA(1)(2)HER2(3)HER2 二、分板塊業績概覽 1. 15,92111.56%20232022355657.1%32.7%mRNA 1,66012.17%1,4289.56%(1)mRNA(2)Gland Pharma(3)(4)301 2,51922.16%15.82%1,79211.26% 145.05% 223.40% 3 VEROmRNA CHO PD-1 PD-1(ES-SCLC)(ES-SCLC)PD-1(MAA)(MSI-H)(sqNSCLC)(ES-SCLC)ESCC20232(ESCC)III(ASTRUM-007)—Nature Medicine82.92023(ASCO) Combo+Global+11(sqNSCLC)(ES-SCLC)(LS-SCLC)(ES-SCLC)(LS-SCLC)IIIPD-1(SCLC)FDA(EC) PD-1295001,500556202331002019KGbioKGbioPD-1102023812Syneos Health CAR-T12B(r/r LBCL) CAR-TKite PharmaCAR-TYescartaB(r/rLBCL)500906025140 202361284.3%83.2%58.4%YescartaZUMA-7New England Journal Of Medicine176.082r/rLBCL(SOC)27.4%B(DLBCL)NCCN(CSCO)B(DLBCL)NCCN(CSCO)I (r/r iNHL))2021 CAR-TFKC889(r/r MCL)Br/r ALL20223202212 ADCRNA FS-1502HER2FHER2IIIHER2I67HER2ORR53.7%PFS15.5FS-1502HER2FS-1502HER2II MEK1/2FCN-159IIFCN-159IIIINF1I202347FCN-159II/IIFCN-159IORR45.1%FCN-159II 2023413III20231VeroGMP Gland PharmaCDMOCenexiCDMO102Gland Pharma7FDA DaxibotulinumtoxinART002Tenapanor(NDA)(BLA) CMO/MAH (Argesun)WHOPQWHOPQGMP504009FDAGMP20238FDA(Pre-License Inspection)FDA(Pre-Approval Inspection) FOPEXFESFES/FOPEX CMCINNOX ScientificAdvisory BoardSABSABSAB9SAB20236SAB ADCRNAAIFICFirst-in-classBICBest-in-class 5104334(NDA)7(IND)542PCT234 (ASCO)(CSCO)(EHA) 7036 2FCN-159NF1I2023420237 3FCN-437cI 120234HLX208BRAF V600E(LCH)Erdheim-Chester(ECD) 220237OP0595IIII 320237Tenapanor(CKD) 7DaxibotulinumtoxinART002 317—20237 2. 2,21545.11%5687.27%11483.69% (1) (Sisram Medical)17219(Sisram Medical)1.71%8.50% (Sisram Medical)(Sisram Medical)SopranoTitaniumAlma OpusBeautiFillFDAAlma Veil20236(Sisram Medical) (Breas) Vivo123 3420236 (SisramMedical)(Sisram Medical)90202372% (2) PCR-TF-A7000 SeriesGlycotest HCC PanelPOCTpanelpanel 3. 3,1277.20%–151236–268174 6,4489 HISSaaS TPAthird party administrator 4. 300,9506,8934,10415.10%10.67%11.12% 225,43314.71% 62,95417.27% C11,352202259917,69715.86% 5. (IFC)506,0004,000 三、核心競爭力分析 1.FICBIC3,5001,8002,88413.48% 2.BDIP 3. 四、報告期內主要經營情況 1 149.81%4.21 223.79%4.170.04(1)(2)PD-1SisramMedical(3) 338122.13% 430716.80% 2(1) 2,1347502,884(%)13.48(%)15.82(%)26.01 (2) 2,51945722.16%15.82%1,79230120.19%11.26% 29.32% 1 (1) (2) 3 (1) Alma LasersAlma HKPhotonMed HKAlma HKPhotonMed HKAlma Lasers (2) 38,591 29.05%2022123127.18% 32202212311,981 五、報告期內ESG進展情況 1 ESGESG2023MSCI ESGAESGA–—AA2022ESGTop 202022ESG (EHS)EHSEHSEHSEHSEHS ESG12B20236906025140500300Artesun245SPAQ-CO ESG 20238ESGESG 六、2023年下半年經營展望 2023 20234INInnovationInternationalizationIntelligentizationIntegration BD 13Vero 2023 2023 2023 2023 七、可能面對的風險 ICH 1. BD 2. GMP 3. 1. 2022FDAAI/ML